Ahead of the keenly anticipated independent panel set to discuss Aimmune’s peanut allergy immunotherapy on Friday, FDA staff issued a predictable review on Wednesday, highlighting the potential safety and tolerability issues associated with the product, while backing its efficacy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,